Eupraxia Pharmaceuticals Inc. (EPRX)

NCM – Real Time Price. Currency in USD

7.61

+0.19 (2.56%)

At close: May 12, 2026, 4:00 PM EDT

8.40

+0.79 (10.38%)

After-hours: May 12, 2026, 7:43 PM EDT

06.05.2026

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue architecture (which is a measure of fibrosis) EoEHSS sub scores for inflammation demonstrated improvements in all reported cohorts at both 12 weeks (n=31) and 36 weeks (n=27) EoEHSS sub scores for tissue architecture (fibrosis) demonstrated improvements across most reported cohorts at 12 and 36 weeks The largest response in both the inflammatory and the architectural (fibrosis) sub scores was seen at the highest dose tested VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first release of sub score data from the Eosinophilic Esophagitis Histologic Scoring System (“EoEHSS”) in its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE").

05.05.2026

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data reported by Eupraxia demonstrated a relationship between the number of injections of EP-104GI and the overall improvements in the EREFS findings A consistent response in both the inflammatory and fibrotic sub scores of EREFS was demonstrated for patients who received 20 injections. This also represents the number of injections being studied in the placebo-controlled Phase 2b portion of the RESOLVE trial VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”).

01.05.2026

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia's current CMO.

22.04.2026

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company will present 4 abstracts at Digestive Disease Week (“DDW”) Annual meeting being held May 2-5, 2026 in Chicago, Illinois. Clinical data will be presented from the ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis (“EoE”).

02.04.2026

New Strong Sell Stocks for April 2nd

ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.

23.03.2026

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair on Monday initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products.

13.03.2026

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise.

Eupraxia Pharmaceuticals Inc. (EPRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

New Strong Sell Stocks for April 2nd

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

New Strong Sell Stocks for April 2nd

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Videos

No Data

Press releases

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Search stocks

Eupraxia Pharmaceuticals Inc. (EPRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

New Strong Sell Stocks for April 2nd

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

New Strong Sell Stocks for April 2nd

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Videos

No Data

Press releases

Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results